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Abstract
Introduction and objective. There have been many studies published recently on obesity and the risk of renal cancer; 
however, the epidemiological evidence for such an association has not been consistent. Therefore, a systematic review 
was conducted of the prospective cohort studies to assess the association between obesity and the risk of renal cancer 
incidence and death.  
Materials and methods. A search was conducted of the PubMed database and references to published studies from 
inception until May 2013. Guidelines for Assessing Quality in Prognostic Studies on the Basis of Framework for Potential 
Biases were followed for quality assessment of studies included in the systematic review.  
Results. Twenty eligible studies were identified and included in the systematic review. Among the 20 selected studies, 
overall study quality was high. Although the evidence from the prospective cohort studies, linking obesity with renal 
cancer incidence, has not been entirely consistent, there is a convincing body of data for a positive relationship. Moreover, 
cumulative data is compelling for a strong positive association between obesity and fatal renal cancer.  
Conclusions. There is a relatively consistent amount of evidence that obesity increases the risk of renal cancer and fatal 
renal cancer. Further research is needed as better understanding of mechanisms by which obesity may influence renal 
cancer development and progression will aid the fostering of strategies for prevention and treatment of one of the most 
lethal human malignancies.
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INTRODUCTION
Being overweight and obese have become major public health 
challenges worldwide [1, 2, 3]. It has recently been estimated 
that overweight (body mass index (BMI) ≥25 kg/m²) affects 
more than one billion people, and more than 300 million of 
them are considered obese (BMI ≥30 kg/m²) [4]. The trend 
has been continuing to escalate over the last 20 years, both 
in the United States and Europe, where the prevalence of 
obesity among adults has doubled [5, 6].
Being overweight and obese are recognised risk factors 
for many chronic medical conditions and several types of 
cancer, including colorectal, endometrial and prostate [7, 
8, 9, 10, 11, 12]. Their potential link to renal cancer, which 
represents 2–3% of all cancers in the developed countries, 
with 88,400 new cases of renal cell carcinoma and 39,300 
kidney cancer-related deaths in the European Union in 2008, 
has attracted the attention of many clinicians [13, 14, 15, 16, 
17]. As a result, a large number of studies have been published 
recently, with three-quarters of the world’s publications 
written over last decade.
The evidence for an association between obesity and 
renal cancer incidence and mortality, however, has not 
been consistent. This may result, in part, from the nature 
of epidemiologic studies, particularly case-controlled or 
retrospective, which are more prone to a number of biases. 
In the absence of randomised trials of weight-change 
interventions, large well-constructed prospective cohort 
analyses would instead provide the highest level of evidence.
Therefore, to address the issues described above, a 
systematic review was carried out of the prospective cohort 
studies on body weight and the risk of renal cancer incidence 
and mortality.
OBJECTIVE
This review sought to answer the question: ‘What evidence 
is there for an association between obesity and renal cancer 
incidence and mortality?’
MATERIALS AND METHOD
A systematic review of prospective cohort studies was 
undertaken in order to accurately identify, evaluate and 
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summarise the findings of all relevant studies. To ensure 
the complete and transparent reporting of this systematic 
review, the Preferred Reporting Items for Systematic Review 
and Mata-Analyses (PRISMA) checklist was used as a tool 
to guide the structure of the review [18].
Search strategy. A comprehensive search strategy was used on 
the Medline/PubMed electronic database from its inception 
until May 2013. Additionally, the search was complemented 
by scanning the reference lists of the identified studies and 
the reference lists of previous systematic reviews [19, 20, 21].
All human research articles published in English were taken 
into consideration, not classified as review, meta-analysis, 
editorial, comment, letter, guideline, or news. The search 
strategy included the following terms: obesity, overweight, 
BMI, nutrition disorder, diet, nutrition assessment, risk, 
incidence, mortality, kidney cancer, renal cancer, renal cell 
cancer, renal carcinoma and renal cell carcinoma.
To be included in the review, studies had to fulfill the 
following criteria:
1) have a prospective design;
2) be a cohort study;
3) exposure of interest was weight or BMI at baseline and/or 
at the end of follow-up; 
4) the outcome of interest was a renal cancer and/or fatal 
renal cancer;
5) hazard ratio (HRs) estimates with 95% confidence intervals 
(CIs) or, alternatively, continuous relative risk (RR) 
estimates (with 95% Cls), or alternatively, RR estimates 
(with 95% Cls).
Data extraction. The following data was extracted from 
each study: last name of the first author, publication year, 
country where the study was conducted, cohort size, duration 
of follow-up, how BMI or body weight was assessed, age at 
baseline, per cent of overweight and obese subjects, number 
of renal cancer and fatal renal cancer cases, HRs or RR 
estimates with corresponding 95% Cls and p values.
Quality assessment. Guidelines for Assessing Quality in 
Prognostic Studies on the Basis of Framework for Potential 
Biases were followed for quality assessment of studies 
included in the systematic review [22]. The potential risk 
for bias was evaluated within the 6 following domains:
(i) study participation;
(ii) study attrition;
(iii) prognostic factors measured;
(iv) outcome measurement; confounding measurement and 
account;
(v) analysis.
Two authors performed quality assessment independently. 
There was no disagreement between the two assessments.
RESULTS
Study selection. A flow chart of the selection of eligible 
studies is given in Figure 1.
Eligibility assessment was performed independently by 2 
reviewers, in duplicate. The search strategy yielded 15,185 
#19019_35108 AAEM_2_2015 / Corrected
Figure 1. Flow diagram of studies identified. 
Records identified through
electronic database searching
= 1,5175
Additional records identified 
through manual searches of the 
bibliographies of selected 
publications=10
218 studies for analysis of 
title and abstracts after 
duplicates removed
170 studies excluded based on 
title and/or abstract
48 full-text articles 
assessed for eligibility
20 studies included in 
qualitative synthesis 
28 full-text articles excluded:
Not a prospective cohort study=19
Overlapping studies=5
Relation of weight with cancer not  
provided=4
Figure 1. Flow diagram of studies identified
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citations, of which 218 were considered potentially relevant. 
170 of these were excluded after screening titles and abstracts. 
The full text of the remaining 48 studies was assessed; of 
those, 19 were rejected, as the study was not a prospective 
cohort, and 4 studies did not report on the relation of weight 
and/or BMI with renal cancer and/or fatal renal cancer. To 
avoid duplicate information from overlapping studies, 5 
studies we removed because their results were pooled or 
updated. The remaining 20 studies were included in the 
presented review [23–42]. A chronological overview of the 
eligible studies is provided in Table 1.
Table 1. Characteristics and results of prospective cohort studies of the association between anthropometric measures and renal cancer incidence 
and mortality
First 
author
Year
Study 
location
Cohort 
size and 
gender 
Follow-
up
BMI 
Measured 
or Self-
reported
Age 
range 
Percent 
overweight 
and obese at 
baseline
No of 
cases 
Reported HRs(a) or RR (b) 
for renal incidence
Reported 
(95%Cl) 
and
p value
Reported 
HRs (a) 
or RR (b) 
for renal 
cancer 
death
Reported 
(95%Cl) and
p value
Leiba 2013 Israel 1,110,835 
(M)
15.9 Measured 16-19 12.1% BMI>25 274(I)
?(D)
1.16 for           a BMI=25.0-
27.4
2.43 for BMI≥27.5
(0.72-1.87)
P=0.54
(1.54-3.83)
p<0.001
? ?
Joh 2011 USA 118,177 
(W)
32 Self-
reported
30-55 ? 330(I) 
?(D)
                        a
1.00 for BMI<30 
1.22 for BMI≥30
? ? ?
Sawada 2010 Japan 99462 
(M+W)
13.5 Self-
reported
40-69 27.4% BMI≥25 139(I) 
?(D) 
Men:               a
1.39 for BMI=25-26.9
1.99 for BMI≥27
Women:
1.55 for BMI≥25
(0.73-2.63)
(1.04-3.81)
(0.76-3.18)
p=?
? ?
Adams 2008 USA 320,618 
(M+W)
8.2 Self-
reported
50-71 ? 1022(I)
(M)
344(I) (W)
?(D)
1.49 for           b BMI=25-
<27.5
1.67 for BMI=27.5-<30
1.97 for BMI=30-<35
2.56 for BMI≥35
(1.19-1.88)
(1.32-2.12)
(1.56-2.50)
(1.95-3.36)
p<0.0005
? ?
Song 2008 Korea 152,772 
(W)
8.75 Measured 40-64 ? 111(I) 
?(D)
1.74 for           a BMI=23.0-
24.9
1.74for BMI=25.0-26.9
1.37 for BMI=27.0-29.9
2.61 for BMI≥30
(0.94-3.22)
(0.92-3.29)
(0.66-2.84)
(1.06-6.41)
p=?
? ?
Reeves 2007 UK 1,222,630 
(W)
5.4 (I)
7.0 (D)
Self-
reported
50-64 35.6% (ov)
17.9%(ob)
723(I)
382(D)
1.10 for           b BMI=25-
<27.5
1.19 for BMI=27.5-<30
1.52 for BMI≥30
(0.94-1.28)
(0.99-1.44)
(1.31-1.77)
p=?
1.14 for       
b BMI=25-
27.4
1.30 for 
BMI=27.5-
29.9
1.71 for 
BMI≥30
(0.92-1.42)
(1.01-1.68)
(1.39-2.09) 
p=?
Luo 2007 USA 140,057 
(W)
7.7 Measured 50-79 ? 269(I) 
?(D)
1.2 for             b BMI=25-
29.9
1.5 for BMI=30.0-34.9
1.6 for BMI≥35
(0.9-1.7)
(1.0-2.1)
(1.1-2.4) 
p =0.01
? ?
Setiawan 2007 Hawaii 75,162 
(M)
85,964 
(W)
8.3 Self-
reported
45-75 Men:
42.5%(ov)
13.8(ob)
Women:
30.1%(ov)
18.0%(ob)
220(I) (M)
127(I) (W) 
?(D)
Men:               b
1.14(ov)
1.76(ob)
Women:
2.03(ov)
2.27(ob)
(0.84-1.55)
(1.20-2.58)
p=0.005
(1.31-3.15)
(1.37-3.47)
p=0.001
? ?
Samanic 2006 Sweden 362,552 
(M)
19 Measured ? ? 734(I) 
?(D)
1.28(ov)          b
1.82(ob)
(1.10-1.49)
(1.41-2.35)
? ?
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First 
author
Year
Study 
location
Cohort 
size and 
gender 
Follow-
up
BMI 
Measured 
or Self-
reported
Age 
range 
Percent 
overweight 
and obese at 
baseline
No of 
cases 
Reported HRs(a) or RR (b) 
for renal incidence
Reported 
(95%Cl) 
and
p value
Reported 
HRs (a) 
or RR (b) 
for renal 
cancer 
death
Reported 
(95%Cl) and
p value
Pischon 2006 8 
European 
countries
348,550 
(M+W)
6.0 Measured 
and for 
part self-
reported
25-70 25.1% 
BMI≥26.0
155(I) (M)
132(I) (W)
Men:               b
0.67 for BMI=25.4-27.0
0.84 for BMI=27.1-29.3
1.22 for BMI≥29.4
Women:
1.99 for BMI=26.0-29.0
2.25 for BMI≥29.1
(0.39-1.18)
(0.49-1.43)
(0.74-2.03)
p=?
(1.03-3.88)
(1.14-4.44) 
p=?
? ?
Lukanova 2006 Sweden 33,424 
(M)
35,362 
(W)
8.2 Measured 29-61 Men:
46%(ov)
11%(ob)
Women:
31% (ov)
13% (ob)
25(I) (M)
20(I) (W)
Men:               b
1.30(ov)
3.63(ob)
Women:
0.92(ov)
1.79 (ob)
(0.51-3.56)
(1.23-10.66) 
p=0.02
(0.31-2.58)
(0.55-5.27)
P=0.37
? ?
Flaherty* 2005 USA 48,953 
(M)
12 Self-
reported
40-75 52.5%(ov)
7.8%(ob)
110(I) 2.4 for             b BMI=25.0-
27.9
2.1 for BMI=28.0-29.9
2.1 for BMI≥30
(0.9-6.8)
(0.7-6.6)
(0.7-6.8)
p=0.19
? ?
Oh 2005 Korea 781,283 
(M)
10 Measured ≥20 ? 562(I) 1.31 for           b BMI=25.0-
26.9
1.82 for BMI=27.0-29.9
1.42 for BMI≥30
(1.02-1.67)
(1.37-2.52)
(0.59-3.46)
p<0.001
? ?
Bjørge 2004 Norway 2,001,230 
(M+W)
23 Measured 14-74 ? 3821(I)
(M)
2632(I) 
(W)
Men:               b
1.18(ov)
1.55(ob)
Women:
1.32(ov)
1.85(ob)
(1.11-1.26)
(1.36-1.76) 
p<0.001
(1.21-1.45)
(1.66-2.06) 
p<0.001
? ?
Van Dijk 2004 Nether-
lands
120,852 
(M+W)
9.3 Self-
reported
55-69 ? 275(I) 0.92 for           b BMI=25-
26.9
1.46 for BMI=27-29.9
1.04 for BMI≥30
(0.61-1.38)
(0.97-2.21)
(0.54-1.99)
P=0.04
? ?
Niko-
demus
2004 USA 34,637 
(W)
15 Self-
reported
55-69 ? 124(I) 1.46 for           b BMI=25.0-
27.4
1.87for BMI=27.4-30.6
2.49 for BMI≥30.6
(0.77-2.74)
(1.02-3.41)
(1.39-4.44)
p=0.0001
? ?
Calle 2003 USA 900,053 
(M+W)
16 Self-
reported
≥30 ? ?(I)
837(D) 
(M)
473(D) 
(W)
? ? Men:          b 
1.18 for 
BMI=25.0-
29.9
1.36 for 
BMI=30-
34.9
1.70 for 
BMI=35.0-
39.9
Women:
RR=1.33 for 
BMI=25.0-
29.9
1.66 for 
BMI=30-
34.9
1.70 for 
BMI=35.0-
39.9
4.75 for 
BMI≥40.0
91.02-1.37)
(1.06-1.74)
(0.99-2.92)
P=0.002
(1.08-1.63)
(1.23-2.24)
(0.94-3.05)
(2.50-9.04)
p<0.001
Table 1. Characteristics and results of prospective cohort studies of the association between anthropometric measures and renal cancer incidence 
and mortality (Continuation)
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Study characteristics. The selected 20 prospective cohort 
studies on renal cancer were published between 1978 – 2013 
and involved a total of 8,716,689 subjects. In 15 studies, the 
source of population was the general population [25, 26, 27, 
28, 29, 30, 32, 33, 35, 36, 37, 38, 39, 40, 42]; one population 
was a cohort of university students [41]; one was military 
recruits [23] and 3 were professional groups [24, 31, 34]. 
Three studies analysed a potential relationship between 
weight and renal cancer in men only [23, 31, 35], while 5 
limited their investigation solely to women [24, 27, 28, 29, 
38]. Almost all populations were more than 90% Caucasian; 
3 studies included only Asians [25, 27, 35] and 2 multiethnic 
populations [23, 30].
In one out of the 20 studies only weight and no BMI 
analysis was performed [41]. Anthropometric variables were 
measured in 9 studies [23, 27, 29, 31, 33, 35, 36, 40, 41]; in 10 
studies they were self-reported [24, 25, 26, 28, 30, 34, 36, 37, 
38, 39, 42]; and in one they were measured or self-reported 
[32]. A relationship between body weight and the risk of renal 
cancer and fatal renal cancer was analysed in one study [28]. 
In 17 studies, only incidence of renal cancer in relation to 
body weight was evaluated [23, 24, 25, 26, 27, 29, 30, 31, 32, 
33, 34, 35, 36, 37, 38, 40, 41] and 2 studies examined solely the 
association between body weight and the risk of fatal renal 
cancer [39, 42]. The ascertainment of incidental renal cancer 
was made through linkage to cancer registries in 11 studies 
[23, 26, 28, 30, 31, 33, 35, 36, 37, 38, 40]. One study relied 
on self-reported diagnosis [41]. In 4 studies, self-reported 
diagnosis was verified by linkage with the cancer register or 
medical records [24, 26, 29, 34]. A mixed system of linkage 
to cancer and pathology registers, health insurance records 
and self-reported diagnosis, depending on the study centre 
considered, was used in one study [32]. The ascertainment 
of fatal renal cancer cases was made through linkage to 
death register in 1 study [28]. One study relied on personal 
enquires successively verified by linkage with death registers 
[42], and personal enquires or death registers, depending 
on the length of follow-up period considered, were used in 
one study [39].
Study synthesis and analysis. Among the 20 selected studies, 
the overall study quality was high. Assessment of the risk of 
bias across the studies is presented in Table 2.
A marked positive relationship between anthropometric 
variables and renal cancer risk in men was reported in 9 
studies [23, 25, 26, 30, 31, 33, 35, 36, 41], whereas in women 
First 
author
Year
Study 
location
Cohort 
size and 
gender 
Follow-
up
BMI 
Measured 
or Self-
reported
Age 
range 
Percent 
overweight 
and obese at 
baseline
No of 
cases 
Reported HRs(a) or RR (b) 
for renal incidence
Reported 
(95%Cl) 
and
p value
Reported 
HRs (a) 
or RR (b) 
for renal 
cancer 
death
Reported 
(95%Cl) and
p value
Møller 1994 Denmark 43,965 
(M+W)
1-4.8 Measured >0 ? 79(I) Men:               b
1.2 (ob)
Women:
2.0(ob)
(0.7-1.8)
(1.5-2.6)
p=?
? ?
Whitte-
more
1985 USA 51,477 
(M+W)
16-50 Measured col-
lege
? Men:
77(I)
31(D)
Women
0(I) 0(D)
1.2 for             b BW>180 
lbs
(1.0-1.3)
p=?
? ?
Lew 1978 USA 750,000 
(M+W)
13 Self-
reported
>30 ? ?(I)
?(D)
? ? Men:           
b
1.63 for 
RBW=110-
119%
1.39 for 
RBW120-
129
1.51 for 
RBW=130-
139
Women:
1.09 for 
RBW=110-
119%
1.30 for 
RBW-120-
129
1.85 for 
RBW=130-
139
2.03 for 
RBW>140%
?
Key: BMI=body mass index; HRs= hazard ratios; RR=relative risk; Cl=confidence interval; p=p value; 
M=men; W=women; I= renal cancer incidence; D= renal cancer death;  Ov=overweight (BMI 25-29.9 kg/m²); Ob=obese (BMI ≥30kg/m²); BW=body weight; RBW=actual weight/average weight; 
a= reported hazard ratios; b=reported relative risk;
Follow-up time is given in years; Subjects’ age range is given in years and refers to age at the time of study entry (baseline)
*=only male cohort evaluated as female subjects’ data is updated in the study by Joh HK et al.
Table 1. Characteristics and results of prospective cohort studies of the association between anthropometric measures and renal cancer incidence 
and mortality (Continuation)
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in 10 studies [25, 26, 27, 28, 29, 30, 32, 36, 38, 40]. A modest 
association between kidney cancer and increased BMI 
in male and female subjects was found in one study [37]. 
There was no association, between baseline anthropometric 
variables and total renal cancer incidence in women in 3 
studies [24, 33, 41], whereas obese males were found to have 
a similar risk for developing renal cancer as individuals with 
normal weight in 3 studies [32, 34, 40].
A positive relationship between anthropometric variables 
and fatal renal cancer in men was observed in 2 studies [39, 
42], whereas 3 studies reported on a higher risk for kidney 
cancer death in obese women, when compared with female 
subjects with normal BMI [28, 39, 42].
DISCUSSION
This systematic review presents epidemiological evidence on 
the potential role of abnormal body weight in the etiology 
of renal cancer. In order to provide more conclusive data, 
and reduce the risk of selection and information bias, the 
presented assessment was restricted to prospective cohort 
studies only, and excluded case-control studies. In all, there 
were 20 studies included in this review. The overall study 
quality was high. In one study, the cohort size was greater 
than 2,000,000 subjects, in 2 – >1,000,000 individuals and 
in 3 – > 700,000. Their follow-up period varied from 5.4 – 
23 years.
The abundance of data gathered in this systematic review 
supports the hypothesis that obesity may increase the risk 
of both renal cancer and fatal renal cancer, suggesting an 
important role for obesity in the initiation and progression 
of this neoplasm. The pathology underlying the association 
between obesity and increased risk of renal cancer, however, 
remains unclear. To-date, several mechanisms have been 
proposed, one of which suggests the involvement of insulin 
and insulin-like growth factor-1 (IGF-1], known to have 
potent cancer-promoting effects [43]. Moreover, oestrogens, 
as well as polymorphism and genotypic changes of the 
oestrogen receptor alpha gene, may also play a role [44].
In addition, lipid peroxidation, which is elevated in obese 
people, has been proposed to be involved in renal cancer 
development in experimental models; lipid peroxidation of 
the proximal renal tubules has also been demonstrated to be 
a necessary mechanistic pathway in chemically-induced renal 
carcinogenesis [45]. Byproducts of lipid peroxidation have 
been shown to react with renal DNA to form adducts, which 
subsequently can damage DNA [46]. This, in turn, may lead 
to mutations in proto-oncogenes and/or tumor suppressor 
genes, and result in changing a normal cell into one with a 
malignant phenotype [47].
Adipose tissue not only stores energy, but also functions 
as an endocrine organ [48]. Adiponectin, leptin and resistin 
are adipocyte-secreted peptide hormones that may influence 
renal cancer development through their demonstrated 
effects on inflammation, insulin resistanc, cell growth and 
proliferation [49].
Finally, obesity is related to an increased risk of 
hypertension, which has been shown to be a risk factor for 
renal cancer development, most likely independent from 
increased weight [50].
Strengths and limitations of the review. The presented study 
has several methodological strengths, namely:
1) the focused review question;
2) a comprehensive and systematic literature search;
3) the collaboration of a multidisciplinary team of 
urologists, endocrinologist and health researchers, who used 
explicit and reproducible eligibility criteria and duplicate 
reproducible eligibility decisions and data extractions;
4) inclusion of prospective cohort studies only.
This systematic review did not provide a quantitative 
evaluation of data. Moreover, epidemiological data, even 
if obtained from prospective cohort studies, may not be 
completely deprived of selection and surveillance bias. 
Particularly, studies that failed to use cancer and/or death 
registries to obtain relevant data, would be more prone to 
these types of systematic error.
CONCLUSIONS
In conclusion, there is a relatively consistent amount of 
evidence that obesity increases the risk of renal cancer and 
fatal renal cancer. Further research is needed for better 
understanding of the mechanisms by which obesity may 
influence renal cancer development and progression, and 
will be an aid to the fostering of strategies for the prevention 
and treatment of one of the most lethal human malignancies.
Table 2. Methodological quality of studies included in the systematic 
review
First author
Risk of potential bias detected
Study 
particip-
ation
Study 
attri-
tion
Prognostic 
factors 
measured
Outcome 
measure-
ment
Confound-
ing 
measure-
ment and 
account
Analysis
Leiba No No No No Partly     e No
Joh No No Yes        a Yes          c Partly     f Unsure    h
Sawada No No Yes        a Yes          c No No
Adams No No Yes        a No No No
Song No No No No No No
Reeves No No Yes        a No No No
Luo No No No Yes          c No No
Setiawan No No Yes        a No No No
Samanic No No No No No No
Pischon No No No No No No
Lukanova No No No No No No
Flaherty No No Yes        a Yes          c no No
Oh No No No Yes          c No No
Bjørge No No No No Partly   e,g No
Van Dijk No No Yes        a No No No
Nikodemus No No Yes        a No Partly   e,g No
Calle No No Yes        a No No No
Møller No No Yes        b No Partly   e,g No
Whitemore No No No Yes      c,d Partly   e,g No
Lew No No Yes        a Yes        c Partly   e,g Unsure    h
Unsure= unable to assess for a potential risk for bias due to lack of data; a= anthropometric 
variables self-reported; b= obesity measurements not standardized and based on patient 
appearance; c= possible incompleteness of data; d= possible misclassification of data; 
e=smoking not included in the multivariate analysis; f= BMI<30 served as a reference level; 
g=hypertension not included in multivariate analysis; h= confidence interval and p value 
not reported;
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